SERIAL EVALUATION OF SERUM PROTEIN PROFILE FOLLOWING BREAST CANCER TREATMENT

乳腺癌治疗后血清蛋白谱的系列评估

• 批准号: 7378580
• 负责人: DAVID N KRAG
• 金额: $ 5.05万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-09 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378580
• 关键词: blood; blood proteins; breast neoplasms; proteins; surgery

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Recent studies on proteins in blood have demonstrated subtle changes in the protein profile between individuals that do have and individuals that do not have breast cancer. The primary goal of this clinical trial is to determine whether blood proteins are altered in patients with breast cancer and how long it takes for the alteration to normalize following surgical treatment of breast cancer. In the future, this may be a very important test to determine the staging of cancer and the effectiveness of breast cancer treatment. In this clinical study, the surgeon or a blood drawing technician will remove a sample of blood. A total of about 10 to 15 milliliters of blood will be removed and processed specifically per protocol. This will occur before surgery and additionally after surgery at 2 weeks, 4 weeks, and monthly for 6 months after surgery (8 draws in total). The goal of this trial is to determine the presence of changes in the protein profile in blood. The objectives of this trial are: Determine the prevalence of breast cancer type serum protein profile in breast cancer patients prior to surgery. Determine the time course of normalization of serum protein profile from cancer-type to normal-type

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。最近对血液中蛋白质的研究表明，患有乳腺癌的个体和没有患乳腺癌的个体之间的蛋白质谱发生了微妙的变化。这项临床试验的主要目的是确定乳腺癌患者的血液蛋白是否发生改变，以及在乳腺癌手术治疗后这种改变需要多长时间才能恢复正常。在未来，这可能是确定癌症分期和乳腺癌治疗有效性的一项非常重要的测试。在本临床研究中，外科医生或抽血技术人员将采集血样。总共将取出约10至15毫升血液并根据方案进行专门处理。这将在术前进行，并在术后2周、4周和术后6个月每月进行一次（共8次）。这项试验的目的是确定血液中蛋白质谱的变化。本试验的目的是：确定乳腺癌患者手术前乳腺癌类型血清蛋白谱的患病率。确定血清蛋白谱从癌症型到正常型正常化的时间过程